France Grants Compassionate Access to Gene Therapy LUMEVOQ®

December 22, 2025 | Paris, France — GenSight Biologics announced that France’s medicines safety authority has granted Compassionate Use Authorization (CUA/AAC) for GS010/LUMEVOQ®, its investigational gene therapy for ND4 Leber Hereditary Optic Neuropathy (LHON). The authorization enables named-patient early access for eligible individuals suffering from this rare, blinding mitochondrial disease, addressing a profound unmet medical need in the absence of approved therapeutic alternatives.

Science Significance

GS010/LUMEVOQ® (lenadogene nolparvovec) is a mitochondrial gene therapy designed to restore visual function by targeting the ND4 mitochondrial mutation, the most common and severe genetic cause of LHON. Leveraging a proprietary Mitochondrial Targeting Sequence (MTS) platform, the therapy delivers a functional ND4 gene to retinal ganglion cells via a single intravitreal injection per eye. This approach addresses the root genetic defect responsible for rapid and often irreversible vision loss, distinguishing LUMEVOQ® as a first-in-class strategy in mitochondrial ophthalmology. The compassionate use decision reflects the scientific maturity and translational readiness of the program.

Regulatory Significance

The Autorisation d’Accès Compassionnel (AAC) is a national French early access mechanism that allows patients with serious, rare, or disabling diseases to receive investigational therapies prior to marketing authorization when no suitable alternatives exist. Granting AAC requires evidence of a favorable benefit–risk profile and is evaluated on a named-patient basis by the French medicines agency. For GS010/LUMEVOQ®, this authorization confirms regulatory confidence in the therapy’s safety and potential efficacy while imposing strict oversight obligations, including traceability, pharmacovigilance, and quality controls consistent with cGxP requirements for Advanced Therapy Medicinal Products (ATMPs).

Business Significance

From a business standpoint, compassionate access represents a strategic inflection point for GenSight Biologics. Early access programs can strengthen stakeholder confidence, generate real-world clinical experience, and support market readiness ahead of formal commercialization pathways. While GS010/LUMEVOQ® is not commercially available in any country, AAC implementation positions GenSight to engage clinicians, treatment centers, and regulators in a controlled setting. The authorization also reinforces the company’s long-term value proposition in gene therapy for retinal neurodegenerative diseases and central nervous system disorders.

Patients’ Significance

For patients with ND4-LHON, the authorization is profoundly meaningful. LHON typically presents in young adults and leads to sudden, severe vision loss, often progressing to legal blindness with devastating impacts on independence, employment, and quality of life. With no approved therapies available, compassionate access to GS010/LUMEVOQ® offers timely hope for eligible patients, particularly when treatment is initiated within defined windows from onset. While access is controlled and individualized, the decision acknowledges the urgent patient need and the potential of gene therapy to alter the course of a previously untreatable disease.

Policy Significance

The AAC decision highlights the role of early access policies in balancing innovation, safety, and equity for rare disease populations. By enabling controlled access to promising ATMPs, regulators support responsible innovation while maintaining robust oversight. The case of GS010/LUMEVOQ® underscores how national compassionate use frameworks can complement EU-wide regulatory pathways, fostering patient-centric access without undermining evidence standards. It also reinforces policy commitments to rare disease research, where traditional development timelines may not align with urgent clinical needs.

The granting of Compassionate Use Authorization for GS010/LUMEVOQ® marks a pivotal step for GenSight Biologics and for patients affected by ND4 Leber Hereditary Optic Neuropathy. By enabling early, regulated access to a novel mitochondrial gene therapy, French regulators have affirmed the therapy’s scientific promise and regulatory readiness under cGxP standards. As GenSight advances toward broader authorization pathways, the AAC program exemplifies how science-driven regulation and patient-focused policy can converge to deliver meaningful impact in rare, vision-threatening diseases.

Source: GenSight Biologics press release